TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Brentuximab vedotin has evidence of efficacy in patients with TNFRSF8 Expression in mature T-cell and NK-cell non-hodgkin lymphoma [5].

TNFRSF8 Expression is an inclusion criterion in 17 clinical trials for hodgkin lymphoma, of which 13 are open and 4 are closed. Of the trials that contain TNFRSF8 Expression and hodgkin lymphoma as inclusion criteria, 8 are phase 1 (6 open), 5 are phase 1/phase 2 (4 open), and 4 are phase 2 (3 open) [5].

TNFRSF8 Expression is an inclusion criterion in 14 clinical trials for anaplastic large cell lymphoma, of which 10 are open and 4 are closed. Of the trials that contain TNFRSF8 Expression and anaplastic large cell lymphoma as inclusion criteria, 7 are phase 1 (6 open), 2 are phase 1/phase 2 (0 open), 4 are phase 2 (4 open), and 1 is phase 3 (0 open) [5].

TNFRSF8 Expression is an inclusion criterion in 12 clinical trials for peripheral T-cell lymphoma, of which 10 are open and 2 are closed. Of the trials that contain TNFRSF8 Expression and peripheral T-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 9 are phase 2 (8 open) [5].

TNFRSF8 Expression is an inclusion criterion in 9 clinical trials for mycosis fungoides, of which 7 are open and 2 are closed. Of the trials that contain TNFRSF8 Expression and mycosis fungoides as inclusion criteria, 7 are phase 1 (6 open), 1 is phase 2 (1 open), and 1 is phase 3 (0 open) [5].

TNFRSF8 Expression is an inclusion criterion in 8 clinical trials for classical hodgkin lymphoma, of which 7 are open and 1 is closed. Of the trials that contain TNFRSF8 Expression and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 7 are phase 2 (6 open) [5].

TNFRSF8 Expression is an inclusion criterion in 8 clinical trials for peripheral T-cell lymphoma, not otherwise specified, of which 8 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 4 are phase 1 (4 open) and 4 are phase 2 (4 open) [5].

TNFRSF8 Expression is an inclusion criterion in 6 clinical trials for angioimmunoblastic T-cell lymphoma, of which 6 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and angioimmunoblastic T-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 4 are phase 2 (4 open) [5].

TNFRSF8 Expression is an inclusion criterion in 6 clinical trials for enteropathy-associated T-cell lymphoma, of which 6 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and enteropathy-associated T-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 5 are phase 2 (5 open) [5].

TNFRSF8 Expression is an inclusion criterion in 5 clinical trials for lymphoma, of which 2 are open and 3 are closed. Of the trials that contain TNFRSF8 Expression and lymphoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 4 are open and 1 is closed. Of the trials that contain TNFRSF8 Expression and non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [5].

TNFRSF8 Expression is an inclusion criterion in 5 clinical trials for sezary syndrome, of which 4 are open and 1 is closed. Of the trials that contain TNFRSF8 Expression and sezary syndrome as inclusion criteria, 5 are phase 1 (4 open) [5].

TNFRSF8 Expression is an inclusion criterion in 4 clinical trials for adult T-cell leukemia/lymphoma, of which 4 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].

TNFRSF8 Expression is an inclusion criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain TNFRSF8 Expression and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

TNFRSF8 Expression is an inclusion criterion in 3 clinical trials for hepatosplenic T-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and hepatosplenic T-cell lymphoma as inclusion criteria, 3 are phase 2 (3 open) [5].

TNFRSF8 Expression is an inclusion criterion in 3 clinical trials for primary cutaneous T-cell non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 3 clinical trials for primary mediastinal B-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and primary mediastinal B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 2 clinical trials for aggressive non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and aggressive non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [5].

TNFRSF8 Expression is an inclusion criterion in 2 clinical trials for anaplastic large cell lymphoma, ALK-negative, of which 2 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and anaplastic large cell lymphoma, ALK-negative as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 2 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [5].

TNFRSF8 Expression is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1 (2 open) [5].

TNFRSF8 Expression is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 1 is open and 1 is closed. Of the trials that contain TNFRSF8 Expression and follicular lymphoma as inclusion criteria, 2 are phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 2 clinical trials for follicular T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and follicular T-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 2 clinical trials for nasal type extranodal NK/T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and nasal type extranodal NK/T-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) [5].

TNFRSF8 Expression is an inclusion criterion in 2 clinical trials for primary cutaneous anaplastic large cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain TNFRSF8 Expression and primary cutaneous anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 0 are open and 1 is closed. Of the trial that contains TNFRSF8 Expression and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 2 (0 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, ALK-positive, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and anaplastic large cell lymphoma, ALK-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains TNFRSF8 Expression and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for lymphomatoid papulosis, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and lymphomatoid papulosis as inclusion criteria, 1 is phase 1 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for lymphomatous adult T-cell leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and lymphomatous adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains TNFRSF8 Expression and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains TNFRSF8 Expression and mast cell leukemia as inclusion criteria, 1 is phase 2 (0 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for nodal peripheral T-cell lymphoma with TFH phenotype, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and nodal peripheral T-cell lymphoma with TFH phenotype as inclusion criteria, 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for primary cutaneous CD30-positive T-cell lymphoproliferative disorder, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and primary cutaneous CD30-positive T-cell lymphoproliferative disorder as inclusion criteria, 1 is phase 1 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for primary cutaneous follicle center lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and primary cutaneous follicle center lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for primary cutaneous gamma-delta T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and primary cutaneous gamma-delta T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for subcutaneous panniculitis-like T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF8 Expression and subcutaneous panniculitis-like T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TNFRSF8 Expression is an inclusion criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TNFRSF8 Expression and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].